Skip to main content

Effectiveness of Bariatric Surgery and Incretin-based Therapies on Cardiovascular Outcomes in Patients with Obesity: A Systematic Review and Network Meta-Analysis

In brief

Surgery and incretin drugs link to 43% and 38% lower mortality

Across 40 studies involving more than 1.9 million adults with obesity, bariatric surgery and incretin-based drugs were each associated with lower mortality and fewer major cardiovascular events than controls. The analysis found no significant mortality difference between the strategies, but most evidence was observational, highly variable, and rated very low confidence, so the apparent benefits are not a reliable head-to-head comparison.

Journal
European journal of preventive cardiology (Q1)
Published
17 November 2026
Study design
Systematic review of cohort studies
Evidence level
Level 2, Moderate (CEBM 2a)
Authors
Anastasios Roumeliotis, Nikolaos Vythoulkas-Biotis, Alexios Gianakodimos, Evangelos Oikonomou, Ourania Katsarou, Loukia Pliouta, et al.
PMID
43043854
DOI
10.1093/eurjpc/zwag588

Why clinicians should know about it

  • Picked for Bariatric and Metabolic Surgery (paper of the day, 19 November 2026): Directly compares surgery and incretin therapies on cardiovascular outcomes

Abstract

BACKGROUND: Bariatric surgery and pharmacological weight-loss therapies improve cardiometabolic risk factors. However, direct head-to-head comparisons assessing their impact on cardiovascular outcomes remain limited. We performed an exploratory meta-analysis to compare bariatric surgery and pharmacological weight-loss therapies on major clinical outcomes in adults with obesity. METHODS: A systematic literature search using PubMed and Scopus databases was conducted. Randomized and observational studies comparing bariatric surgery or incretin receptor agonists with controls were included in the analysis. The primary outcomes were all-cause mortality and MACE. A frequentist random-effects network meta-analysis was conducted across three nodes. RESULTS: A total of 40 studies, comprising more than 1.9 million patients, were included in the meta-analysis. Compared with control, bariatric surgery was associated with a significant reduction in all evaluated outcomes, including all-cause mortality (HR:0.57, 95%CI:0.51-0.65), MACE (HR:0.54, 95%CI:0.45-0.64), cardiovascular mortality, heart failure hospitalization, myocardial infarction, and stroke. Incretin receptor agonists were also associated with lower all-cause mortality (HR:0.62, 95%CI:0.52-0.74), lower MACE (HR:0.75, 95%CI:0.61-0.92) and reduced heart failure hospitalization. All-cause mortality-representing the most direct and clinically relevant endpoint-did not differ significantly between the two strategies in the exploratory network meta-analysis. Importantly, the network estimates should be cautiously interpreted, given the predominance of observational evidence, substantial heterogeneity, and very low confidence across all comparisons. CONCLUSION: Bariatric surgery and incretin receptor agonists are associated with substantial reductions in major cardiovascular outcomes in adults with obesity. In head-to-head comparisons, no significant differences were observed in all-cause mortality and stroke. Both strategies provide clinically meaningful benefits.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.